Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Novo Nordisk A/S - Reduction of the share capital | |||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 24 Apr 2019 | Back to overview list |
||||||||||||||||||||||||||||
Bagsværd, Denmark, 24 April 2019 - At Novo Nordisk's Annual General Meeting on 21 March 2019, it was decided to reduce the company's B share capital from DKK 382,512,800 to DKK 372,512,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 480,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 372,512,800. The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced. Further information
Attachment |
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |